References
1. Ficha Técnica Stelara [Internet]. [consultado 2024 Jul 12]. Available from: https://www.ema.europa.eu/en/documents/product-information/stelara-epar-product-information_en.pdf
2. Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease. N Engl J Med. 2016 Nov 17;375:1946-1960.
3. Sands Bruce E., Sandborn William J., Panaccione Remo, et al. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med.2019 Sep 26;381:1201–14.
4. Hanauer SB, Sandborn WJ, Feagan BG, et al. IM-UNITI: Three-year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. J Crohns Colitis. 2020 Jan 1;14:23-32.
5. Panaccione R, Danese S, Sandborn WJ, et al. Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy. Aliment Pharmacol Ther. 2020 Dec;52:1658-1675.
6. Fumery M., Peyrin-Biroulet L., Nancey S., et al. Effectiveness and Safety of Ustekinumab Intensification At 90 Mg Every Four Weeks In Crohn’s Disease: A Multicenter Study. J. Crohn’s Colitis. 2020;15:222–227.
7. Torres J, Bonovas S, Doherty G, et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Medical Treatment. Journal of Crohn’s and Colitis. 2020 Jan 1;14:4–22.
8. Amiot A, Filippi J, Abitbol V, et al. Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study. Aliment Pharmacol Ther. June 2020;51:1039–1046.
9. Ollech JE, Normatov I, Peleg N, et al. Effectiveness of Ustekinumab Dose Escalation in Patients With Crohn’s Disease. Clin Gastroenterol Hepatol. 2021 Jan;19:104-110.
10. Kopylov U, Hanzel J, Liefferinckx C, et al. Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous maintenance therapy. Aliment Pharmacol Ther. 2020 Jul;52:135-142.
11. Battat R, Kopylov U, Bessissow T, et al. Association Between Ustekinumab Trough Concentrations and Clinical, Biomarker, and Endoscopic Outcomes in Patients With Crohn's Disease. Clin Gastroenterol Hepatol. 2017 Sep;15:1427-1434.e2.
12. Hermida Pérez B, Mancebo Mata A, de Jorge Turrión MÁ, et al. Efficacy and safety of intravenous ustekinumab maintenance therapy in Crohn's disease. Rev Esp Enferm Dig. 2023 Jun;115:340-341.
13. Argüelles-Arias F, Delgado TV, Pérez BM, et al. Intravenous ustekinumab maintenance treatment in patients with loss of response to subcutaneous dosing. Therap Adv Gastroenterol. 2023 Aug 24:16:17562848231191670
14. Suárez Ferrer C, Arroyo Argüelles J, Rueda García JL, et al. Intensification with Intravenous Ustekinumab in Refractory Crohn’s Disease. J Clin Med. 2024 Jan 24;13:669.
15. Siffledeen, J., Singh, S., Shulman, S.M. et al. Effect of Suboptimal Disease Control on Patient Quality of Life: Real-World Data from the Observational IBD- PODCAST Canada Trial. Dig Dis Sci. 2024 May;69(5):1636-1648
16. Meserve J, Ma C, Dulai PS, et al. Effectiveness of Reinduction and/or Dose Escalation of Ustekinumab in Crohn's Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022 Dec;20:2728-2740.e1.
17. Admin S. Intravenous ustekinumab as maintenance treatment is effective in patients with partial or loss of response to optimized ustekinumab sc. European Crohn´s and Colitis Organisation - ECCO - P433.
18. Yiu TH, Ko Y, Pudipeddi A, et al. Meta-analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2024 Jun;59:1312-1334.
19. McDonald C, Kerr H, Gibbons E, et al. Higher Ustekinumab Levels in Maintenance Therapy are Associated with Greater Mucosal Healing and Mucosal Response in Crohn's Disease: An Experience of 2 IBD Centers. Inflamm Bowel Dis. 2024 Mar 1;30:423-428.
20. Vasudevan A, Tharayil V, Raffals Lh, et al. Systematic Review and Meta-analysis: The Association Between Serum Ustekinumab Trough Concentrations and Treatment Response in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2024 Apr 3;30:660-670.